Replies to post #659354 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Whether the PIM or the HE, both were very broad, so i think it is likely they get a broad designation for relevant brain tumor indications. It also helps them if more patients are eligible in a number of ways and likely increases scale and therefore economic viability for a company providing the services/product, which in the long-run improves cost competitiveness of NWBO with anything else that might arrive.